PAREXEL Reports First Quarter Fiscal Year 2012 Financi... ( BOSTON Oct. 31 2011 /- PAREXEL Intern...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

PAREXEL Reports First Quarter Fiscal Year 2012 Financial Results

Date:10/31/2011

BOSTON, Oct. 31, 2011 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) today announced its financial results for the first quarter ended September 30, 2011.

For the three months ended September 30, 2011, PAREXEL’s consolidated service revenue increased by 6.4% to $314.7 million, compared with $295.8 million in the prior year period. Excluding the positive impact from foreign exchange movements of $7.2 million, revenue increased 3.9%. The Company reported operating income, as reported under Generally Accepted Accounting Principles (GAAP) of $12.5 million, or 4.0% of consolidated service revenue, in the first quarter of Fiscal Year 2012, versus GAAP operating income of $30 million, or 10.1% of consolidated service revenue, in the comparable quarter of the prior fiscal year. GAAP net income for the quarter ended September 30, 2011 totaled $9.6 million, or $0.16 per diluted share, compared with GAAP net income of $17.8 million, or $0.30 per diluted share, for the quarter ended September 30, 2010. GAAP net income in the quarter decreased by 46.3% year-over-year, and earnings per diluted share decreased by 46.7%.

The financial results of the September quarters in Fiscal Year 2012 and Fiscal Year 2011 each included special items related to restructuring activities, as detailed in the financial charts within this press release. Excluding the impact of these special items, adjusted operating income in the first quarter of Fiscal Year 2012 was $15.2 million, or 4.8% of consolidated service revenue. Excluding these special items in the prior year period, adjusted operating income was $29.6 million, or 10.0% of consolidated service revenue, in the first quarter of Fiscal Year 2011. On this adjusted basis, operating income in the quarter ended September 30, 2011 declined 48.8% year-over-year. Adjusted net income in the
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
2. New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership
3. PAREXEL and National University of Singapore Establish Program in Singapore to Meet Increasing Demand in Asia for Clinical Research Talent
4. PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call
5. Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar
6. PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results
7. PAREXEL Achieves 100th Asian Ethnobridging Study Milestone
8. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2011 Earnings Release and Conference Call
9. PAREXEL International to Present at Goldman Sachs Healthcare Conference and Jefferies Global Healthcare Conference
10. PAREXEL Invites Public to Listen to Live Webcast of Its Investor Day June 2, 2011
11. PAREXEL Reports Third Quarter Fiscal Year 2011 Financial Results

Post Your Comments:

(Date:5/20/2013)... , May 20, 2013 Hyland ... healthcare industry by creating the Multi-Disciplinary Clinical Leadership ... variety of medical experts with diverse healthcare experience, ... healthcare industry to create new software solutions that ... specific needs of patients and staff. ...

(Date:5/20/2013)... 20, 2013 Enrollment of patients with Type ... dose-finding clinical trial of product candidate NewMet ™, ... for Type 2 diabetes. Elcelyx expects to complete enrollment ... June. Results of the trial,s primary endpoint of change ... and the read-out for long-term glucose lowering and weight ...

(Date:5/20/2013)... Rhythm announced today the presentation of results from ... gastroparesis symptoms among diabetic patients in the U.S. than ... patients with both type 1 and type 2 diabetes, ... the more common type 2 disease. ... Professor of Medicine at Harvard Medical School and Director ...

Breaking Medicine Technology:Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions 2 Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2 Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3 Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4 Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2 Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3 Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4

[0] Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions [0] Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes [0] Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.

... 2008 Senesco,Technologies, Inc. ("Senesco" or the "Company") ... Mirmira, one of the Company,s funded researchers, will,be ... data,at two conferences in April 2008. Dr. Mirmira, ... of Virginia, is presently the,Eli Lilly Endowed Chair ...

... of Athletes ... - Team Type 1, - Spreads Messages of Hope to Others ... Ultimate Goal of Tour de France Competition, BRIDGEWATER, ... injection) will now become the primary sponsor of,Team Type 1, a team of amateur ...

Cached Medicine Technology:Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences 2 Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences 3 Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 2 Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 3 Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 4 Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 5

Senesco's Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R)

(Date:5/20/2013)... University of Southampton has shown that blind and visually ... to that used by bats and dolphins, to determine ... is published in the journal Hearing Research , ... could help blind people with spatial awareness and navigation. ... impairment and how to optimise echolocation ability in order ...

(Date:5/20/2013)... 6Webs.com is the leading supplier of ... 6Webs.com recently completed their assessments of the top alarm ... annually and the top home security system companies are ... technology, equipment and warranties to mention a few. ... team completed the home security reviews, numerous people claimed ...

(Date:5/20/2013)... Dermatologists are saying that new federally mandated labeling ... choices when it comes to products that provide ... required by the U.S. Food and Drug Administration ... will protect against skin cancer in addition to ... a sunscreen is water-resistant, according to the American ...

(Date:5/20/2013)... VHA Inc., the national health care ... population health improvement, announced a new offering to ... pursue population health management with a strategic ... the transition to value-based models of care. As ... of services, the offering integrates VHA expert advisory ...

(Date:5/20/2013)... Researchers at Lund University in Sweden have mapped ... atherosclerotic disease. No studies have previously examined whether ... study looked at coronary heart disease, ischemic stroke, ... in individuals whose siblings and parents have suffered ... showed that heredity is highest for atherosclerosis of ...

Breaking Medicine News(10 mins):Health News:New study finds blind people have the potential to use their 'inner bat' to locate objects 2 Health News:Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com 2 Health News:Revised Sunscreen Labels Should Help Consumers Make Wiser Choices 2 Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2 Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3 Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4

[0] New study finds blind people have the potential to use their 'inner bat' to locate objects [0] Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com [0] Revised Sunscreen Labels Should Help Consumers Make Wiser Choices [0] VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings [0] Atherosclerotic disease heredity mapped in nationwide study

... MKL ) reported diluted net loss per share ... to diluted net income per share of $9.26,for the ... was $2.63 for the,nine months ended September 30, 2008 ... the same period of 2007. The results for both ...

... more targeted prevention efforts, researcher says , , TUESDAY, Nov. 4 ... Hispanics in the United States, a new study shows. , ... a type of beverage that is more associated with risky ... developed to target that beverage and that type of drinking," ...

... HAVEN, Conn., Nov. 4 VION,PHARMACEUTICALS, INC. (OTC Bulletin ... on Thursday, November 6, 2008 to,discuss its 2008 third ... 8:30 a.m. Eastern Time., To participate in the ... 213-8858 for international callers), at least 15 minutes,before the ...

... 4, 2008 Proactive measures can reduce hip fracture rates ... as 50 percent -- among those at risk, according to ... was published online on November 3 by The Journal ... , The largest study of its kind, the five-year study ...

... be Held at 8 a.m. EST -, SHENZHEN, ... (NYSE: NPD ) ("China Nepstar" or the "Company"), ... of directly operated,stores, announced today that the Company will ... before the market opens on,Wednesday, November 26, 2008., ...

... (Nasdaq: IRIX ) today reported financial results for ... the third quarter of 2008 was $12.0 million, an ... quarter of 2007. The,Company recorded net loss of $0.2 ... of 2008, an improvement over the net loss of ...

Markel Reports Third Quarter and Nine-Month Results Study Shows Hispanics Prefer Beer Vion Updates Conference Call Information Healthy bones program reduces hip fractures by 37 percent China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26 IRIDEX Reports Third Quarter 2008 Financial Results

... IMMULITE 1000 assays are designed ... and IMMULITE 1000, continuous random ... simplicity in both design and ... found in a wide variety ...

... Digoxin Assay is a homogeneous ... in the quantitative analysis of ... plasma. Kits are packaged specifically ... COBAS MIRA, COBAS MIRA S, ...

The Emit 2000 Digoxin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of digoxin in human serum or plasma. Kits are conveniently packaged in Olympus Reagent Cartridges ...

Liquichek Rheumatoid Factor Control is a liquid trilevel control designed to monitor rheumatoid factor testing procedures, including nephelometric and latex agglutination methods....

Medicine Products:

IMMULITE Phenytoin Emit 2000 (Convenience Pack) Digoxin Assay OSR Digoxin Assay Liquichek Rheumatoid Factor Control